secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-151979
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Therapeutics appoints John Doux, M.D. to Board of Directors
--------------------------------------------------------------------

- Board increased to 7 members; Dr. Doux appointed as Class III director with term expiring at 2026 Annual Meeting.
- Dr. Doux is a board-certified dermatologist and analyst at Palo Alto Investors LP since 2004.
- Granted option to purchase 6,000 shares vesting in equal monthly installments over 36 months.
- Previously served on Palvella's board before reverse merger (2019-2022).
- Board determined Dr. Doux independent under Nasdaq listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/0001193125-26-151979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526151979/pvla-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-151979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer